ondansetron has been researched along with Mental Disorders in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is a highly selective 5-HT3 antagonist, which has recently become available for the control of chemotherapy-induced emesis." | 2.38 | [Ondansetron--the first highly selective 5-HT3 antagonist in therapy of psychiatric diseases]. ( Broocks, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Khalil, M | 1 |
| Sack, A | 1 |
| Elson, R | 1 |
| Pleat, J | 1 |
| Czech, B | 1 |
| Kucewicz, E | 1 |
| Frank, M | 1 |
| Broocks, A | 1 |
2 reviews available for ondansetron and Mental Disorders
| Article | Year |
|---|---|
[Neuropsychiatric complication after surgical procedures--literature review].
Topics: Antipsychotic Agents; Cardiac Surgical Procedures; Delirium; Humans; Mental Disorders; Nervous Syste | 2003 |
[Ondansetron--the first highly selective 5-HT3 antagonist in therapy of psychiatric diseases].
Topics: Brain; Humans; Imidazoles; Mental Disorders; Ondansetron; Receptors, Serotonin; Serotonin Antagonist | 1992 |
1 other study available for ondansetron and Mental Disorders
| Article | Year |
|---|---|
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents; Arrhythmias, Cardiac; Burns; Comorbidity; Drug Int | 2020 |